Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Pandora Q2 EBIT rises 14% to DKK 1.46 billion; revenue increases 2% to DKK 7.22 billion

Pandora Q2 EBIT rises 14% to DKK 1.46 billion; revenue increases 2% to DKK 7.22 billion

ReutersReuters2026/08/12 15:37
  • Pandora Q2 2026 revenue rose 2% to DKK 7.22 billion, while organic growth slowed to 3% from 8% a year earlier.
  • EBIT climbed 14% to DKK 1.46 billion, lifting the EBIT margin 2.1 percentage points to 20.3%.
  • Gross margin widened to 80.5% due to a partial refund on a US IEEPA tariff claim; excluding it, gross margin was 78.2%.
  • Guidance for 2026 was raised to 0%-3% organic growth and a 22%-23% EBIT margin, reflecting the one-off tariff income.
  • CEO Berta de Pablos-Barbier said early actions to re-energize growth are showing progress; Q3 like-for-like growth ran at mid-single digits.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pandora A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121130OMX_____CNEWS_EN_GNW1001257310_en) on August 12, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas

A study published in The Lancet indicates that Trump's efforts to lower drug prices in the United States may force pharmaceutical companies to raise prices internationally or exit certain markets, potentially leading to a significant reduction in the approximately $11.6 billion saved annually by Medicare.

智通财经2026/09/14 00:46
Saving in the US, paying globally? Industry research warns: Trump’s push to lower drug prices could instead incentivize pharmaceutical companies to raise prices overseas